1042. Safety of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical S...

por Braun, Tricia, Guthmueller, Beth, Harvey, Adam J
Publicado 2021

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection

por Dubberke, Erik R., Orenstein, Robert, Khanna, Sahil, Guthmueller, Beth, Lee, Christine
Publicado 2022

706. An Ad Hoc Subgroup Analysis of a Phase 3, Open-Label Study Indicates Efficacy and Safety of Fecal Microbiota, Live-jslm in Participants With Recurrent Clostridioides difficile...

por Fischer, Monika, Thul, Joan, Guthmueller, Beth, Sandrock, Christian, Van Hise, Nicholas, Tillotson, Glenn S
Publicado 2023

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials

por Lee, Christine, Louie, Thomas, Bancke, Lindy, Guthmueller, Beth, Harvey, Adam, Feuerstadt, Paul, Khanna, Sahil, Orenstein, Robert, Dubberke, Erik R.
Publicado 2023

702. Efficacy of Fecal Microbiota, Live-jslm After Receipt of Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Trial

por Reveles, Kelly R, Gonzales-Luna, Anne J, Golan, Yoav, Alonso, Carolyn D, Guthmueller, Beth, Tan, Xing, Bidell, Monique, Pokhilko, Victoria, Crawford, Carl, Skinner, Andrew M
Publicado 2023